Meeting
2018 ASCO Annual Meeting
Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
Authors
Leena Gandhi
NYU Perlmutter Cancer Center, New York, NY
Leena Gandhi , Kristen Aufiero Ramirez , Paul Schwarzenberger , Toni Ricciardi , Mary J. Macri , Aileen Ryan , Ralph Rudolph Venhaus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03164772
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9107)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9107
Abstract #
TPS9107
Poster Bd #
428b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.
First Author: Guru P. Sonpavde
Poster
2016 ASCO Annual Meeting
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).
First Author: Ghassan K. Abou-Alfa
Poster
2024 ASCO Annual Meeting
The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.
First Author: Mengni Guo
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe